Since the height of the West African Ebola epidemic in 2014—the worst outbreak in the disease’s history—Johnson & Johnson has worked to accelerate efforts to develop an Ebola vaccine. The Company has now received the first approval of its Ebola vaccine regimen from the Marketing Authorization from the European Commission, which is the executive arm of the European Union. Discover the steps that J&J has taken toward enabling broader access to its vaccine regimen for the people who need it most, a